ReviewCurrent cardiology reports2012
Molecular imaging of amyloidosis: will the heart be the next target after the brain?
Review in Current cardiology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Preclinical and preliminary clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Myocardium From Patients With ATTR Amyloidosis Produces Less Force Secondary to Increased Fibrosis.JACC. Basic to translational science · 2025Article
- Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits.International journal of molecular sciences · 2023Review
- Semi-Quantification of Myocardial Uptake of Bone-Seeking Agents in Suspected Cardiac Amyloidosis.Journal of cardiovascular development and disease · 2023Article
- Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment.EXCLI journal · 2023Review
- Reproducibility and repeatability of assessment of myocardial light chain amyloidosis burden usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET.Nuclear medicine and molecular imaging · 2021Review
- Multi-modality imaging of cardiac amyloidosis: Contemporary update.World journal of radiology · 2020Review
- Positive Myocardial Uptake of Bone Scintigraphic Agents Associated with Cardiac Amyloidosis: Frequency of Positive Uptake Data Based on Daily Clinical Practice.Annals of nuclear cardiology · 2020Article
- Multi-Modality Imaging in Dilated Cardiomyopathy: With a Focus on the Role of Cardiac Magnetic Resonance.Frontiers in cardiovascular medicine · 2020Review
- The Cardiorenal Axis: Myocardial Perfusion, Metabolism, and Innervation.Current cardiology reports · 2019Review
- Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.Current cardiology reports · 2018Review
- Standardization ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.Journal of translational medicine · 2017Article
- The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update.JACC. Cardiovascular imaging · 2017Review
- Dual-Energy SPECT and the Development of Peptide p5+14 for Imaging Amyloidosis.Molecular imaging · 2017Article
- Role of Imaging in Evaluating Infiltrative Heart Disease.Current treatment options in cardiovascular medicine · 2017Review
- Clinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology.Diagnostics (Basel, Switzerland) · 2016Review
- Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging.Frontiers in neurology · 2016Review
- Shoulder pad sign and asymptomatic hypercalcemia in a patient with end-stage kidney disease.Clinical medicine insights. Case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidosis is a heterogeneous group of diseases with a common feature of extracellular deposition and infiltration of different types of amyloid fibrils in various organs. For example, Alzheimer's disease is characterized by deposition of amyloid β in the brain. Radiolabeled positron emission tomography (PET) tracers, mainly derivatives of thioflavin-T, were recently introduced for identification of amyloid β plaques in Alzheimer's patients. Such advances of amyloid β plaque imaging of the brain may shed light into imaging of other organs in amyloidosis patients, such as the heart. Cardiac infiltration of amyloid confers poor clinical outcomes, which renders early diagnosis for appropriate clinical management. At present, nuclear imaging of cardiac amyloidosis is predominantly accomplished with bone-seeking radiotracers, such as 99m-technetium-labeled pyrophosphate ((99m)Tc-PYP), 99m-technetium-methylene diphosphonate ((99m)Tc-MDP), and 99m-technetium-3,3,-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD), with conflicting results in terms of diagnostic performance, with the exception for (99m)Tc-DPD, which may differentiate light-chain amyloidosis from transthyretin-related cardiac amyloidosis. Although other non-bone-seeking radiotracers such as iodine-123-labeled amyloid P component ((123)I-SAP), 123-iodine-Meta-iodobenzylguanidine ((123)I-mIBG), 99m-technetium-labeled protease inhibitor, and indium-111-labeled amyloid antibodies have also shown some success in identifying cardiac amyloidosis, the future, however, may lie in labeling derivatives of thioflavin-T. With the recent success of visualizing deposition of amyloid β in the brain, the US Food and Drug Administration-approved PET imaging agent (18)F-florbetapir may be used to target cardiac amyloidosis next.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.